Treatment optimization and genomic outcomes in refractory severe aplastic anemia treated with eltrombopag

Eltrombopag (EPAG) received approval from the US Food and Drug Administration for the treatment of refractory severe aplastic anemia (rSAA) based on treatment of 43 patients with doses escalating from 50 to 150 mg daily for 12 weeks. Response kinetics suggested that more prolonged administration of...

Full beskrivning

Sparad:
Bibliografiska uppgifter
I publikationen:Blood
Huvudupphovsmän: Winkler, Thomas, Fan, Xing, Cooper, James, Desmond, Ronan, Young, David J., Townsley, Danielle M., Scheinberg, Phillip, Grasmeder, Sophia, Larochelle, Andre, Desierto, Marie, Valdez, Janet, Lotter, Jennifer, Wu, Colin, Shalhoub, Ruba N., Calvo, Katherine R., Young, Neal S., Dunbar, Cynthia E.
Materialtyp: Artigo
Språk:Inglês
Publicerad: American Society of Hematology 2019
Ämnen:
Clinical Trials and Observations
Länkar:https://ncbi.nlm.nih.gov/pmc/articles/PMC6566590/
https://ncbi.nlm.nih.gov/pubmed/30992268
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/blood.2019000478
Taggar: Lägg till en tagg
Inga taggar, Lägg till första taggen!

Liknande verk